Trial Profile
Single Arm and Multicenter Clinical Trial to Evaluating the Efficacy and Safety of the Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) for Relapsed or Refractory Neuroblastoma in Children
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Anti GD2 CAR transduced T cells (Primary)
- Indications Neuroblastoma
- Focus Therapeutic Use
- Sponsors Sinobioway Cell Therapy
- 06 Oct 2016 New trial record